Prevention & management of post-operative recurrence in Crohn's disease

Dr Gill Watermeyer IBD Clinic Division of Gastroenterology Department of Medicine Groote Schuur Hospital and University of Cape Town





Post-operative recurrence


- Very common complication of CD (almost ubiquitous)
- Typically at the site of anastomosis or proximal to it

Histologic	Endoscopic	Clinical	Surgical
Within 1 week	90% by 1 year	50% at 5 years	25% at 5 years


Post-operative recurrence

- Early endoscopic recurrence is typically asymptomatic
- Failure to treat subclinical inflammation:
- May result in progressive damage
- By the time symptoms occur this is often irreversible






Prophylaxis vs. placebo



Doherty G, et al. Cochrane Database Syst Rev 2009;CD006873

- Metronidazole
- Effective but often poorly tolerated
- Benefits disappear rapidly on discontinuation
- Thiopurines
- Many side effects, slow onset of action

Anti-TNFs as prophylaxis



Endoscopic recurrence at 1 year


- Small numbers and in reality not as impressive
- After this trial several others were published
- Mostly observational (IFX and ADA)
- Rates of Endoscopic POR at year \pm 20%

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection

Miguel Regueiro,¹ Brian G. Feagan,² Bin Zou,³ Jewel Johanns,³ Marion A. Blank,⁴ Marc Chevrier,³ Scott Plevy,³ John Popp,⁴ Freddy J. Comillie,⁵ Milan Lukas,⁶ Silvio Danese,⁷ Paolo Gionchetti,⁸ Stephen B. Hanauer,⁹ Walter Reinisch,^{10,11} William J. Sandborn,¹² Dario Sorrentino,^{13,14} and Paul Rutgeerts,¹⁵ for the PREVENT Study Group

Gastroenterology 2016;150:1568-1578

Assess efficacy of prophylactic TNFs in preventing POR




Risk stratifying CD patients

- Who should have immediate postoperative prophylaxis
- One size does not fit all


Low risk	Intermediate risk	High risk
> 50 years of age	30 - 50 years of age	Age < 30
Short segment CD (< 20cm)	Longer fibrotic stricture	Myenteric plexitis
Fibrotic stricture	Inflammatory disease	Penetrating or perianal CD
Disease duration > 10 years	Disease duration < 10 years	1 previous surgery
Non-smoker	Non-smoker	Smoker
No prophylaxis	Consider prophylaxis	Prophylaxis

Endoscopy guided treatment



Early endoscopy to guide therapy

- Colonoscopy 6-12 months post surgery
- Therapy initiated/escalated based on severity of POR



Early endoscopy to guide therapy

POCER study: 174 patients post -operatively Patients were labelled 'high' risk or 'low' risk

- High risk if ≥1 of the following factors:
- Smoking
- Perforating disease (abscess, enteric fistula)
- Previous resection


High risk patients received AZA/6-MP or adalimumab (if AZA/6-MP intolerant) Low risk patients received no treatment

POCER study

- 50%: no endoscopy at 6/12 (standard care group)
- 50%: had endoscopy at 6/12 (active care group)
- Treatment escalated depending on Rutgeert's score
- Even if asymptomatic
- No treatment _____ AZA/6-MP
- AZA/6-MP _____ Adalimumab
- Adalimumab ----- Decrease dosage interval

POCER study


Endoscopic recurrence at 18 months




De Cruz P, et al. Lancet 2015; 385: 1406-17

POR in 2017


AGA Guidelines. Gastroenterology 2017;152:271-275



Anti-TNFs vs. Thiopurines in POR



De Cruz P, et al. Lancet 2015; 385: 1406-17



Non-invasive methods to evaluate POR

- Ileocolonoscopy is gold standard
- But it is invasive


ECCO statement 8E

"Calprotectin, trans-abdominal ultrasound, MRE, and CE are emerging as alternative tools for identifying POR" Journal of Crohn's and Colitis, 2017, 135-149

• FC the only one ready for prime time

Faecal calprotectin

- Correlates well with Rutgeert's score
- Can be used to monitor for POR and response to Rx
- Predicts POR with greater accuracy than CRP/CDAI
- Levels > 100 mg/g appear to be the optimal cut off
 NPV 90%
 Wright E, et al. Gastroenterology 2015;148:938-947
- FC does not replace the need for colonoscopy
- Rather serves as a complementary investigation
- Can be measured frequently
- If positive may prompt earlier endoscopy




The future

- Personalised medicine
- Tailored to the individual
- Not just the fore mentioned risk factors
- Predicting POR
- Predicting response to therapy
- Genetics
- Epigenetics
- Microbiome

Microbiome and POR (POCER study)

- Following ileocaecal resection POR was associated with:
- Elevated Proteus in the resection specimen (p = 0.01)
- Reduced Faecalibacterium prausnitzii (p< 0.001)
- Smokers had increased Proteus (p = 0.01) post-op

Wright E, et al. Journal of Crohn's and Colitis, 2017, 191-203



Take home messages

- POR is very common
- Immediate post-op prophylaxis and early Rx are key
- Stratify patients by risk: STOP SMOKING
- Anti-TNFs are the best therapy to date
- As prophylaxis in high risk patients
- Early endoscopy to guide future treatment is recommended to improve outcomes (6-12 months post-op)
- Escalate Rx based on endoscopic recurrence regardless of symptoms
- The future: personalised approach